Jason R Westin

Jason R Westin

UNVERIFIED PROFILE

Are you Jason R Westin?   Register this Author

Register author
Jason R Westin

Jason R Westin

Publications by authors named "Jason R Westin"

Are you Jason R Westin?   Register this Author

55Publications

1879Reads

42Profile Views

A rare case of methotrexate and primaquine co-administration in a mantle cell lymphoma patient.

J Clin Pharm Ther 2019 Oct 20;44(5):800-804. Epub 2019 May 20.

Department of Pharmacy Clinical Services, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jcpt.12849DOI Listing
October 2019

CD5+ diffuse large B-cell lymphoma, NOS: clinical characteristics and outcomes in rituximab era.

Leuk Lymphoma 2019 Sep 18:1-9. Epub 2019 Sep 18.

Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center , Houston , TX , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1663418DOI Listing
September 2019

Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction.

Cell 2019 Jul 4;178(3):699-713.e19. Epub 2019 Jul 4.

Division of Oncology, Department of Medicine, Stanford University, Stanford, CA, USA; Division of Hematology, Department of Medicine, Stanford University, Stanford, CA, USA; Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA, USA; Stanford Cancer Institute, Stanford University, Stanford, CA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cell.2019.06.011DOI Listing
July 2019

Rosai-Dorfman Disease: The MD Anderson Cancer Center Experience.

Clin Lymphoma Myeloma Leuk 2019 Jul 4. Epub 2019 Jul 4.

Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2019.06.013DOI Listing
July 2019

Stage I non-Hodgkin lymphoma: no plateau in disease-specific survival ?

Ann Hematol 2019 May 8;98(5):1169-1176. Epub 2019 Jan 8.

Department of Haematology, Sir Charles Gairdner Hospital, Nedlands, WA, Australia.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00277-018-3571-7
Publisher Site
http://dx.doi.org/10.1007/s00277-018-3571-7DOI Listing
May 2019

Stage I Non-Hodgkin Lymphoma: difference in survival outcome by primary extranodal site of involvement.

Br J Haematol 2019 Apr 5;185(2):334-338. Epub 2018 Jul 5.

Department of Haematology, Sir Charles Gairdner Hospital, Nedlands, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15444DOI Listing
April 2019

Reply to J. Wang et al.

J Clin Oncol 2019 Mar 12;37(9):755-757. Epub 2019 Feb 12.

David M. Kurtz, MD, PhD; Florian Scherer, MD; Michael C. Jin; Joanne Soo; Alexander F.M. Craig, MPhil; Mohammad S. Esfahani, PhD; Jacob J. Chabon, PhD; Henning Stehr, PhD; Chih Long Liu, PhD; Robert Tibshirani, PhD; Lauren S. Maeda, MD; Neel K. Gupta, MD; Michael S. Khodadoust, MD, PhD; Ranjana H. Advani, MD; and Aaron M. Newman, PhD, Stanford University, Stanford, CA; Ulrich Dührsen, MD; and Andreas Hüttmann, MD, University Hospital Essen, Essen, Germany; Michel Meignan, MD, PhD, Hôpitaux Universitaires Henri Mondor, Creteil, France; Olivier Casasnovas, MD, Centre Hospitalier Universitaire, Dijon, France; Jason R. Westin, MD, The University of Texas MD Anderson Cancer Center, Houston, TX; Mark Roschewski, MD; and Wyndham H. Wilson, MD, PhD, National Institutes of Health, Bethesda, MD; Gianluca Gaidano, MD, PhD; and Davide Rossi, MD, PhD, University of Eastern Piedmont, Novara, Italy, Oncology Institute of Southern Switzerland and Institute of Oncology Research, Bellinzona, Switzerland; and Maximilian Diehn, MD, PhD; and Ash A. Alizadeh, MD, PhD, Stanford University, Stanford, CA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.18.01907
Publisher Site
http://dx.doi.org/10.1200/JCO.18.01907DOI Listing
March 2019

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

N Engl J Med 2019 01 1;380(1):45-56. Epub 2018 Dec 1.

From the Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia (S.J.S.); the Hematopoietic Cellular Therapy Program, University of Chicago Medicine, Chicago (M.R.B.); Peter MacCallum Cancer Centre, St. Vincent's Hospital and University of Melbourne, Melbourne, VIC (C.S.T.), and the Royal Prince Alfred Hospital and Department of Medicine, University of Sydney, Sydney (P.J.H.) - both in Australia; Winship Cancer Institute of Emory University, Bone Marrow and Stem Cell Transplant Center, Atlanta (E.K.W.); the Department of Hematology and Oncology, University Hospital of Cologne, Cologne (P.B.), and the Würzburg University Medical Center, Center for Allogeneic Stem Cell Transplantation, Würzburg (S.M.) - both in Germany; the Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Cancer Center, Kansas City (J.P.M.); the Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna (U.J.); James Cancer Hospital and Solove Research Institute, Ohio State University Comprehensive Cancer Center, Columbus (S.J.); the Department of Hematology and Blood and Marrow Transplant, University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco (C.A.); the Department of Lymphoma and Myeloma, Division of Cancer Medicine, University of Texas M.D. Anderson Cancer Center, Houston (J.R.W.); Maisonneuve-Rosemont Hospital, University of Montreal, Montreal (I.F.), and the Juravinski Hospital and Cancer Centre, McMaster University, Hamilton, ON (S.R.F.) - both in Canada; the Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis (V.B.); Karolinska Institutet and University Hospital, Department of Laboratory Medicine/Department of Cell Therapy and Allogeneic Stem Cell Transplantation, Stockholm (S.M.); University of Michigan Comprehensive Cancer Center, Ann Arbor (J.M.M.); the Department of Oncology, Oslo University Hospital, Oslo (H.H.); Novartis Pharma, Basel, Switzerland (S.P., O.A.); Novartis Pharmaceuticals (L.B.P., J.C.) and Novartis Institutes for BioMedical Research (R.A.), East Hanover, NJ; the Department of Hematology, Hospices Civils de Lyon, Université de Lyon, Lyon, France (G.S.); and the Center for Hematologic Malignancies, Oregon Health and Science University Knight Cancer Institute, Portland (R.T.M.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1804980
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1804980DOI Listing
January 2019

Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma.

J Clin Oncol 2018 10 20;36(28):2845-2853. Epub 2018 Aug 20.

David M. Kurtz, Florian Scherer, Michael C. Jin, Joanne Soo, Alexander F.M. Craig, Mohammad Shahrokh Esfahani, Jacob J. Chabon, Henning Stehr, Chih Long Liu, Robert Tibshirani, Lauren S. Maeda, Neel K. Gupta, Michael S. Khodadoust, Ranjana H. Advani, Ronald Levy, Aaron M. Newman, Maximilian Diehn, and Ash A. Alizadeh, Stanford University, Stanford, CA; Florian Scherer, University Medical Center Freiburg, Freiburg; Ulrich Dührsen and Andreas Hüttmann, University Hospital Essen, Essen, Germany; Michel Meignan, Hôpitaux Universitaires Henri Mondor, Creteil; René-Olivier Casasnovas, Hôpital Le Bocage, Centre Hospitalier Universitaire, Dijon, France; Jason R. Westin, University of Texas MD Anderson Cancer Center, Houston, TX; Mark Roschewski and Wyndham H. Wilson, National Cancer Institute, National Institutes of Health, Bethesda, MD; Gianluca Gaidano and Davide Rossi, University of Eastern Piedmont, Novara, Italy; and Davide Rossi, Oncology Institute of Southern Switzerland and Institute of Oncology Research, Bellinzona, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.78.5246DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6161832PMC
October 2018

Dose-Adjusted EPOCH-R and Mid-Cycle High Dose Methotrexate for Patients with Systemic Lymphoma and secondary CNS Involvement.

Br J Haematol 2017 12 9;179(5):851-854. Epub 2016 Aug 9.

Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.14267DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6063086PMC
December 2017

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.

N Engl J Med 2017 12 10;377(26):2531-2544. Epub 2017 Dec 10.

From the University of Texas M.D. Anderson Cancer Center, Houston (S.S.N., J.R.W.); H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (F.L.L., J.C.C.); Washington University and Siteman Cancer Center, St. Louis (N.L.B., A. Ghobadi); University of Miami, Miami (L.J.L., K.V.K.); Stanford University, Stanford (D.B.M., R.L.), City of Hope National Medical Center, Duarte (T.S.), University of California at Los Angeles, Los Angeles (J.M.T.), University of California at San Diego, San Diego (J.E.C.), and Kite Pharma, Santa Monica (A.B., J.R., L.N., Y.J., J.A., M.E., D.C., J.W., W.Y.G.) - all in California; Dana-Farber Cancer Institute, Boston (C.A.J., E.D.J.); Montefiore Medical Center, Bronx (I.B.), and the University of Rochester School of Medicine, Rochester (J.W.F., P.R.) - both in New York; Vanderbilt University Medical Center (O.O.O.) and the Sarah Cannon Research Institute and Tennessee Oncology (I.W.F.), Nashville; Mayo Clinic, Rochester, MN (Y.L., T.E.W.); Loyola University Medical Center, Maywood, IL (P.J.S.); John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ (A. Goy); Cleveland Clinic, Cleveland (B.T.H., M.R.S.); Karmanos Cancer Center, Wayne State University, Detroit (A.D.); University of Iowa Carver College of Medicine, Iowa City (U.F.); Colorado Blood Cancer Institute, Denver (P.M.S.); Banner M.D. Anderson Cancer Center, Gilbert, AZ (J.M.); and Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel (I.A.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1707447DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5882485PMC
December 2017

What to Do With Success? The Optimist's Creed in Relapsed Hodgkin Lymphoma.

Clin Lymphoma Myeloma Leuk 2016 09 8;16(9):483-487. Epub 2016 Jun 8.

Division of Cancer Medicine, Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2016.06.011DOI Listing
September 2016

Treatment of chronic myelogenous leukemia as a paradigm for solid tumors: how targeted agents in newly diagnosed disease transformed outcomes.

Am Soc Clin Oncol Educ Book 2012 :179-85

From the Department of Leukemia; Department of Lymphoma and Myeloma; Department of Investigational Cancer Therapeutics, University of Texas M. D. Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14694/EdBook_AM.2012.32.179DOI Listing
April 2016

Multimodality imaging of Epstein-Barr virus-associated inflammatory pseudotumor-like follicular dendritic cell tumor of the spleen: case report and literature review.

Clin Imaging 2015 May-Jun;39(3):525-8. Epub 2015 Jan 7.

Department of Diagnostic Radiology, Unit 1473, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030-4009. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clinimag.2014.12.021DOI Listing
November 2015

Busting robustness: using cancer's greatest strength to our advantage.

Authors:
Jason R Westin

Future Oncol 2015 ;11(1):73-7

1400 Holcombe Blvd, Unit 0429, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon.14.49DOI Listing
September 2015

Benefit of consolidative radiation therapy for primary bone diffuse large B-cell lymphoma.

Int J Radiat Oncol Biol Phys 2015 May 5;92(1):122-9. Epub 2015 Mar 5.

Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2015.01.014DOI Listing
May 2015

A clinician's guide to double hit lymphomas.

Br J Haematol 2015 Mar 22;168(6):784-95. Epub 2014 Dec 22.

Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.13276DOI Listing
March 2015

Status of PI3K/Akt/mTOR pathway inhibitors in lymphoma.

Authors:
Jason R Westin

Clin Lymphoma Myeloma Leuk 2014 Oct 7;14(5):335-42. Epub 2014 Feb 7.

Division of Cancer Medicine, Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center, Houston, TX. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2014.01.007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4125533PMC
October 2014

It's about time: lessons for solid tumors from chronic myelogenous leukemia therapy.

Mol Cancer Ther 2012 Dec 30;11(12):2549-55. Epub 2012 Nov 30.

Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-12-0473DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4107422PMC
December 2012

Therapy of newly diagnosed follicular lymphoma.

Front Oncol 2012 11;2:188. Epub 2012 Dec 11.

University of Texas MD Anderson Cancer Center Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2012.00188DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3518764PMC
December 2012

Hodgkin lymphoma untreated for six years presenting with tracheoesophageal fistula.

Case Rep Med 2012 2;2012:457908. Epub 2012 Jul 2.

Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://www.hindawi.com/journals/crim/2012/457908/
Publisher Site
http://dx.doi.org/10.1155/2012/457908DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3395413PMC
August 2012

Vive la résistance: stem cells in mantle cell lymphoma.

Leuk Lymphoma 2011 Jun 4;52(6):944-5. Epub 2011 Apr 4.

Department of Lymphoma and Myeloma, University of Texas M D Anderson Cancer Center, Houston, TX 77054, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2011.569622DOI Listing
June 2011

Beyond R-CHOP and the IPI in large-cell lymphoma: molecular markers as an opportunity for stratification.

Curr Hematol Malig Rep 2009 Oct;4(4):218-24

Department of Lymphoma/Myeloma, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Unit #429, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-009-0029-yDOI Listing
October 2009